Quanticate Demonstrates New Outsourcing Strategy and Helpdesk at DIA 2011
Quanticate announces its new Centralized Clinical Data Sciences, an outsourcing strategy at this year’s 47th Annual DIA (Drug Information Association) Meeting, occurring in Chicago from June 19-23.
“Based on Quanticate’s 10-plus years of outsourcing and extensive clinical trial experience, this is an advancement in outsourcing that Quanticate is well placed to deliver. It has benefits in trial design and provides an efficient use of database design. Our outsourcing model can also leverage the latest technologies in cloud computing as well as ensure global regulatory compliance,” said David Underwood, CEO of Quanticate.
Centralized Clinical Data Sciences further develops strategic alliances and functional service provision and allows for easy combining of data from different studies within and across Phases.
In addition to the new outsourcing model, Quanticate is launching a Statistical Consultancy Helpdesk, an online resource that will provide easy access to expert Statistical Consultancy. Either via a dedicated phone line or the Internet, customers will be able to access the helpdesk with ease.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
